TrialInternational journal of colorectal disease2021

Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial).

Chihiro Kosugi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.